The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit further characterization of the safety profile of lorlatinib in participants continuing to receive study intervention
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
76
ALK-positive NSCL treatment
Number of participants with adverse events leading to permanent discontinuation of study intervention
Safety collection in this study will permit further characterization of the safety profile of lorlatinib
Time frame: Baseline up to approximately 5 years
Number of serious adverse events reported for all participants
Safety collection in this study will permit further characterization of the safety profile of lorlatinib
Time frame: Baseline up to approximately 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, United States
The First affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Beijing Chest Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Hunan Provincial Tumor Hospital
Changsha, Hunan, China
General Hospital of Eastern Theater Command
Nanjing, Jiangsu, China
Jilin Cancer Hospital
Changchun, Jilin, China
The first hospital of jilin university
Changchun, Jilin, China
...and 17 more locations